Congress Publications

Abivax’s lead drug candidate, obefazimod (originally known as ABX464), is an investigational drug candidate that has not yet been approved for commercial use in any jurisdiction, but it has already garnered plenty of attention in the industry. The following collection of congress publications are from medical meetings, beginning in 2026.

As data are presented at medical meetings, this page will be updated with applicable posters and oral presentations according to medical meeting embargo guidelines.

The information on this website is intended for healthcare professionals only. It may contain scientific content and medical data not suitable for the general public. Obefazimod is an investigational agent not approved for use by any health regulatory agencies for any indication. By proceeding, you confirm that you are a licensed healthcare professional.

Congress

Digestive Disease Week (DDW) 2026

Presentation

Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active UC: results from the ABTECT-1 and ABTECT-2 phase 3, double-blind, placebo-controlled induction trials

F Magro, BE Sands, S Danese, M Dubinsky, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, L Harlacher, F Scaldaferri, G D’Haens, L Biedermann, L Peyrin-Biroulet

Poster

Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

M Dubinsky, R Atreya, MP Sparrow, S Markovic, C Le Berre, T Hlavaty, X Treton, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, A Armuzzi

Poster

Efficacy and safety of obefazimod in an elderly population with moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

AJ Yarur, H Tilg, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, S Nancey, S Markovic, RA Rocco, L Harlacher, F Magro

Poster

Efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: results in subgroups of prior inadequate response to advanced therapy (ATIR) including or excluding patients with prior JAK-IR from ABTECT Phase 3 induction trials

BE Sands, DT Rubin, L Wolanski, HP Török, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, A De Sa Rolim, F D'Amico, F Baert

Poster

Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials

BE Sands, S Danese, L Peyrin-Biroulet, M Dubinsky, R Atreya, A Armuzzi, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, D Laharie, PS Dulai, DT Rubin, U Seidler

Poster

Improvements in patient-reported fatigue among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 double-blind, placebo-controlled induction trials

M Dubinsky, S Danese, DT Rubin, BE Sands, M Gregus, A Armuzzi, G D’Haens, U Seidler, X Treton, CJ Rabbat, JT Fine, K Shan, CM Dolan, D Jacobstein, F Cataldi, B Siegmund

Poster

Improvements in patient-reported, disease-specific and overall quality-of-life among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod: pooled results from the 8-week ABTECT-1 and ABTECT-2 phase 3 induction trials

BE Sands, R Atreya, L Mihalkanin, P Korga, M Fedurco, U Seidler, X Treton, CJ Rabbat, JT Fine, K Shan, CM Dolan, D Jacobstein, F Cataldi, F Baert

Poster

Obefazimod shows first evidence of dual
anti-inflammatory and anti-fibrotic activity
in murine in vivo and human in vitro models

S Danese, F Magro, B Siegmund, R Atreya, J Santo, A Garcel, S D’Alessio, M Pehrsson, JH Mortensen, M Sorokina Alexdottir, A-C Bay-Jensen, M Asser Karsdal, D Jacobstein, R Mosig, CJ Rabbat, M De La Rosa, F Cataldi, B Verstockt

Poster

Obefazimod enhances miR-124 expression in blood and colon tissue and reduces the key inflammatory cytokines IL-17A and IL-6 in serum of patients with moderate-to-severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials

PS Dulai, S Danese, M Dubinsky, R Atreya, A Abecassis-Borgus, C Apolit, J Sandri, C Belda, P Amin, J Santo, R Mosig, D Jacobstein, F Cataldi, CJ Rabbat, S Howaldt, B Verstockt, G D’Haens, B Siegmund

Congress

European Crohn’s and Colitis Organization (ECCO) 2026

Presentation

Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease

S Danese, F Magro, B Siegmund, R Atreya, J Santo, A Garcel, S D’Alessio, M Pehrsson, JH Mortensen, M Sorokina Alexdottir, A-C Bay-Jensen, M Asser Karsdal, R Mosig, CJ Rabbat, M de la Rosa, F Cataldi, B Verstockt

Presentation

Obefazimod induction therapy for moderately to severely active ulcerative colitis: pooled analysis of inflammatory biomarkers from the two ABTECT Phase 3 double-blind, placebo-controlled induction trials

B Siegmund, R Atreya, F Cataldi, D Jacobstein, J Santo, CJ Rabbat, K Shan, P Miheller, C Gilletta, BG Wojnarska, B Verstockt, F Magro, PS Dulai

Presentation

Impact of baseline disease extent on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from ABTECT-1 and ABTECT-2 Phase 3 trials

S Heeren, PS Dulai, B Neneman, B Bunganic, J Pumprla, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, L Peyrin-Biroulet

Presentation

Improvements in patient-reported, disease-specific and overall quality-of-life among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

F Baert, R Atreya, L Mihalkanin, P Korga, M Fedurco, U Seidler, X Treton, CJ Rabbat, JT Fine, K Shan, CM Dolan, D Jacobstein, F Cataldi, BE Sands

Presentation

Impact of baseline disease duration on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3 trials

G D’Haens, DT Rubin, R Kempinski, J Kieltucki, J Balaz, D Laharie, A Armuzzi, X Treton, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, A Yarur

Presentation

Improvements in patient-reported fatigue among patients with moderately to severely active UC treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 trials

M Dubinsky, S Danese, DT Rubin, BE Sands, M Gregus, A Armuzzi, G D’Haens, U Seidler, X Treton, CJ Rabbat, JT Fine, K Shan, CM Dolan, D Jacobstein, F Cataldi, B Siegmund

Poster

Impact of concomitant corticosteroid use on efficacy and safety of obefazimod at week 8 in moderately to severely active UC

X Treton, M Dubinsky, U Seidler, L Jonaitis, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, F D’Amico, S Lee, DT Rubin

Poster

Pooled analysis of efficacy and safety of once-daily oral obefazimod in North American patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials

BE Sands, M Dubinsky, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, R Panaccione, T Ritter, J Siddiqui, GA Duvall, PS Dulai

Poster

Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials

U Seidler, S Danese, L Peyrin-Biroulet, M Dubinsky, R Atreya, A Armuzzi, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, D Laharie, PS Dulai, DT Rubin, BE Sands

Poster

Improvements in patient-reported bowel urgency and nocturnal bowel movements among patients with moderately to severely active UC treated with obefazimod induction therapy

M Dubinsky, S Danese, DT Rubin, MP Sparrow, T Hlavaty, F Magro, S Nancey, CJ Rabbat, JT Fine, K Shan, CM Dolan, D Jacobstein, F Cataldi, A Armuzzi

Poster

Impact of prior inadequate response to advanced therapies on early symptomatic improvement with obefazimod induction in moderately to severely active UC

R Atreya, BE Sands, DT Rubin, M Dubinsky, A Armuzzi, X Treton, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, T Hlavaty, R Witek, PS Dulai, S Danese

Poster

Continued efficacy improvement beyond induction with once-daily obefazimod: week 8–48 outcomes from the Phase 2b open-label maintenance study, stratified by prior advanced-therapy exposure

A Armuzzi, S Danese, R Atreya, M Dubinsky, BE Sands, PS Dulai, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, DT Rubin

Poster

Obefazimod enhances miR-124 expression in blood and colon tissue and reduces IL-17A and IL-6 in serum of patients with moderate-to-severely active UC

B Siegmund, S Danese, M Dubinsky, R Atreya, A Abecassis-Borgus, C Apolit, J Sandri, C Belda, P Amin, J Santo, R Mosig, D Jacobstein, F Cataldi, CJ Rabbat, S Howaldt, B Verstockt, G D’Haens, PS Dulai

Poster

Impact of prior inadequate response to advanced therapy (ATIR) on the efficacy of obefazimod in patients with moderately to severely active UC

F Baert, DT Rubin, L Wolanski, HP Török, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, A de Sa Rolim, F D’Amico, BE Sands

Poster

Impact of prior advanced therapy inadequate response by drug class on symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled analysis of ABTECT Phase 3 induction trials

S Danese, BE Sands, S Heeren, R Schnabel, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, M Gregus, MP Sparrow, DT Rubin

Poster

Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active UC

F Magro, BE Sands, S Danese, M Dubinsky, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, L Harlacher, F Scaldaferri, G D’Haens, L Biedermann, L Peyrin-Biroulet

Poster

Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

A Armuzzi, R Atreya, MP Sparrow, S Markovic, C Le Berre, T Hlavaty, X Treton, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, M Dubinsky

Poster

Improvements in patient-reported work productivity and activity impairment among patients with moderately to severely active UC treated with obefazimod induction therapy

H Tilg, P Dulai, S Skybalo, V Neshta, S Howaldt, F D’Amico, T Vanasek, M Gregus, CJ Rabbat, JT Fine, K Shan, CM Dolan, D Jacobstein, F Cataldi, B Siegmund

Poster

Impact of baseline Mayo endoscopic subscore on the efficacy of once-daily oral obefazimod in moderately to severely active UC

L Peyrin-Biroulet, BE Sands, A Armuzzi, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, HP Török, S Nancey, G D’Haens, D Laharie, M Dubinsky

Poster

Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active UC

DT Rubin, M Dubinsky, F Scaldaferri, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, O Ramos Junior, O Leoshyk, A de Sa Rolim, Y Bouhnik, R Atreya

Poster

Impact of age on the efficacy and safety of once-daily oral obefazimod in moderately to severely active UC

F Magro, H Tilg, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, S Nancey, S Markovic, RA Rocco, L Harlacher, AJ Yarur

Poster

Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials

F Scaldaferri, U Seidler, X Treton, F D’Amico, A Armuzzi, S Howaldt, S Heeren, R Atreya, F Baert, H Tilg, F Cataldi, D Jacobstein, CJ Rabbat, K Shan, M Cicala